British Journal of Clinical Pharmacology | Page 2

Elena Y Enioutina, Kathleen M Job, Catherine M T Sherwin
No abstract text is available yet for this article.
May 13, 2020: British Journal of Clinical Pharmacology
Einar S Björnsson
No abstract text is available yet for this article.
May 12, 2020: British Journal of Clinical Pharmacology
Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, Anna Spreafico
The development of immune checkpoint inhibitors (ICI) represents a major milestone in immune-oncology. Over the years these agents have demonstrated efficacy in an increasing array of malignancies. Despite this success however, significant challenges remain. Novel approaches to both drug development and trial design are required to incorporate the unique pharmacokinetic and pharmacodynamic properties of ICIs. Further it has also been established that the benefit of ICIs is limited to only a subset of patients...
May 11, 2020: British Journal of Clinical Pharmacology
Geoffrey T Tucker, Carl A Wesolowski
No abstract text is available yet for this article.
May 11, 2020: British Journal of Clinical Pharmacology
Valentí Gómez, Rami Mustapha, Kenrick Ng, Tony Ng
Radiation therapy is an essential component of cancer care, contributing up to 40% of curative cancer treatment regimens. It creates DNA double-strand breaks causing cell death in highly replicating tumour cells. However, tumours can develop acquired resistance to therapy. The efficiency of radiation treatment has been increased by means of combining it with other approaches such as chemotherapy, molecule-targeted therapies and, in recent years, immunotherapy. Cancer-cell apoptosis after radiation treatment causes an immunological reaction that contributes to eradicate the tumour via antigen presentation and subsequent T-cell activation...
May 9, 2020: British Journal of Clinical Pharmacology
Bishoy Kamel, Garry G Graham, Sophie L Stocker, Zhixin Liu, Ken M Williams, Jane E Carland, Kevin D Pile, Richard O Day
AIMS: To examine the pharmacokinetic-phamacodynamic (PK-PD) relationships of plasma febuxostat and serum urate and the effect of a single dose of the drug on renal excretion and fractional clearance of urate (FCU). METHODS: Blood and urine samples were collected at baseline and up to 145 h following administration of febuxostat (80 mg) to healthy subjects (n=9). Plasma febuxostat and serum and urinary urate and creatinine concentrations were determined. Febuxostat pharmacokinetics were estimated using a two-compartment model with first order absorption...
May 9, 2020: British Journal of Clinical Pharmacology
Hiroyuki Muranushi, Junya Kanda, Yasuyuki Arai, Takero Shindo, Masakatsu Hishizawa, Takashi Yamamoto, Tadakazu Kondo, Kohei Yamashita, Kazuo Matsubara, Akifumi Takaori-Kondo
AIMS: We performed the retrospective analysis to clarify the significance of drug monitoring for mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), in prophylaxis for graft-versus-host disease (GVHD) in cord blood transplantation (CBT). METHODS: We retrospectively analyzed the data of 46 patients who underwent first CBT and received GVHD prophylaxis with tacrolimus plus MMF. MPA levels were measured on days 7 and 21, and 24-hour areas under the curve (AUC0-24 ) were estimated...
May 9, 2020: British Journal of Clinical Pharmacology
Pauline Macaire, Justine Paris, Julie Vincent, François Ghiringhelli, Leïla Bengrine-Lefevre, Antonin Schmitt
AIM: Granulocyte colony-stimulating factor (G-CSF) is frequently prescribed to prevent chemotherapy-induced neutropenia, but the administration schedule remains empirical in case of bi-monthly chemotherapy such as FOLFIRINOX regimen. This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule. METHODS: A population PK/PD model was developed to describe individual neutrophils time course from absolute neutrophil counts (ANC) obtained in 40 advanced cancer patients receiving FOLFIRINOX regimen...
May 9, 2020: British Journal of Clinical Pharmacology
Vishal Navani, Nikola A Bowden, Moira C Graves, Andre Van Der Westhuizen
Immune checkpoint blockade has transformed outcomes across solid organ tumours. Monoclonal antibodies targeting the negative inhibitory CTLA-4 and PD-1/PD-L1 axis can lead to deep and durable responses across a number of tumour streams in the advanced setting. This immunotherapy approach is increasingly used earlier in the treatment paradigm. A rapidly evolving regulatory, reimbursement and drug development landscape has accompanied this novel class of immunotherapy. Unfortunately only a small proportion of patients respond meaningfully to these agents...
May 8, 2020: British Journal of Clinical Pharmacology
Daniele Pastori, Evaristo Ettorre, Gregory Y H Lip, Angela Sciacqua, Francesco Perticone, Francesco Melillo, Cosmo Godino, Rossella Marcucci, Martina Berteotti, Francesco Violi, Pasquale Pignatelli
AIMS: To investigate the decline of estimated glomerular filtration rate (eGFR) in patients with atrial fibrillation (AF) treated with Vitamin K antagonists (VKAs) or non-VKAs oral anticoagulants (NOACs). METHODS: Multicentre prospective cohort study including 1,667 patients with non-valvular AF. The eGFR was assessed by the CKD-EPI formula at baseline and during follow-up. The primary endpoint of the study was the median annual decline of eGFR according to VKAs (n=743) or NOACs (n=924) use...
May 8, 2020: British Journal of Clinical Pharmacology
David Back, Catia Marzolini, Catherine Hodge, Fiona Marra, Alison Boyle, Sara Gibbons, David Burger, Saye Khoo
No abstract text is available yet for this article.
May 8, 2020: British Journal of Clinical Pharmacology
Xavier Pourrat, Clémence Leyrat, Benoît Allenet, Brigitte Bouzige, Armelle Develay, Martial Fraysse, Valérie Garnier, Jean-Michel Halimi, Clarisse Roux-Marson, Bruno Giraudeau
AIM: To assess whether a pharmacist intervention associating medication reconciliation at discharge with a link to the community pharmacist reduces drug-related problems (DRP) in adult patients during the 7 days after hospital discharge in 22 university or general hospitals in France. METHODS: We conducted a cluster randomised cross-over superiority trial with hospital units as the cluster unit. The primary outcome was a composite of any kind of DRP (prescription/dispensation, patient error or gap due to no medication available) during the 7 days after discharge, assessed by phone with the patient and community pharmacist...
May 8, 2020: British Journal of Clinical Pharmacology
Ahmet Emre Eşkazan
No abstract text is available yet for this article.
May 7, 2020: British Journal of Clinical Pharmacology
Katherine Z Isoardi, Gregory Polkinghorne, Keith Harris, Geoffrey K Isbister
INTRODUCTION: With rising use worldwide, pregabalin is increasingly implicated in poisoning deaths. We aimed to investigate the clinical effects and complications of pregabalin poisoning. METHODS: This is a retrospective review of patients presenting with pregabalin poisoning to two tertiary toxicology units from 1 July 2014 to 30 June 2019. Patients were identified from prospective databases maintained by both units and data were extracted from these in addition to medical records...
May 6, 2020: British Journal of Clinical Pharmacology
Eline Houben, Bernke Te Winkel, Eric A P Steegers, Ron M C Herings
AIMS: Recent population-based data on drug utilization around pregnancy are lacking. This study aims to examine the prevalence of drug exposure in the Netherlands during the preconception, pregnancy and postpartum periods, with special emphasis on trends of potentially harmful medication over the years. METHODS: A population-based study was conducted using records from the PHARMO Perinatal Research Network. From 1999 to 2017, the proportion of pregnancies during which women used any medication or potentially harmful medication was assessed, overall and stratified by timing of exposure relative to pregnancy and by the year of delivery...
May 6, 2020: British Journal of Clinical Pharmacology
Nadège Neant, Minh Patrick Le, Naïm Bouazza, Florence Gattacceca, Yazdan Yazdanpanah, Catherine Dhiver, Sylvie Bregigeon, Saadia Mokhtari, Gilles Peytavin, Catherine Tamalet, Diane Descamps, Bruno Lacarelle, Caroline Solas
AIMS: The purpose of this study was to assess the antiviral activity of the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination and to describe the pharmacokinetics of rilpivirine and its association with resistance in clinical routine. METHODS: A retrospective multicenter cohort study was performed in both naive and pre-treated HIV patients receiving the once-daily rilpivirine/emtricitabine/tenofovir disoproxil fumarate regimen. Immuno-virologic and resistance data, and rilpivirine plasma trough concentrations were collected over the follow-up...
May 6, 2020: British Journal of Clinical Pharmacology
Tesfahun C Eshetie, Greg Roberts, Tuan A Nguyen, Marianne H Gillam, Dorsa Maher, Lisa M Kalisch Ellett
AIMS: To determine the prevalence of potentially inappropriate medication (PIM) use at hospital admission and discharge, and the contribution to hospital admission among residential aged care facility (RACF) residents with and without dementia. METHODS: We conducted a secondary analysis using data from a multi-hospital prospective cohort study involving consecutively admitted older adults, aged 75 years or older, who were taking five or more medications prior to hospital admission and discharged to a RACF in South Australia...
May 6, 2020: British Journal of Clinical Pharmacology
Simon Grill, Shirin Bruderer, Patricia N Sidharta, Mariya Antonova, Susanne Globig, James Carlson, Armin Schultz, Dénes Csonka
AIMS: To demonstrate the bioequivalence of macitentan/tadalafil fixed-dose combination (FDC) tablets with single-component tablets of macitentan and tadalafil in healthy subjects. METHODS: Studies AC-077-101 and AC-077-103 were single-center, open-label, single-dose, 2-period, randomized, crossover Phase 1 studies conducted in healthy subjects. Two FDCs were investigated: FDC-1 and FDC-2 in Study AC-077-101 and FDC-2 in Study AC-077-103. Both FDCs contained 10 mg/40 mg of macitentan/tadalafil and differed in excipients and coating materials used...
May 6, 2020: British Journal of Clinical Pharmacology
Vikas Modgill, Léa Dormegny, David J Lewis
AIMS: The classical Weber effect describes an increase in adverse reaction (AR) reports after medicinal product authorisation, with a peak in AR reporting at the end of the second year followed by a decline, despite increasing patient exposure. The present study aimed to evaluate the validity of the Weber effect in the context of authorised medicines in a specialty care setting. METHODS: Using six-monthly sales data as a proxy for exposure, the exposure adjusted reporting rates for AR reports for ten selected specialty care medicines were plotted against time...
May 6, 2020: British Journal of Clinical Pharmacology
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson
The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand, programmed cell death-ligand 1 (PD-L1), have been extensively studied. Currently seven monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however, a proportion of patients do not benefit from this treatment...
May 5, 2020: British Journal of Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"